CLINICAL_TRIALS
trial_result
· 2026-02-02
Clinical Trial Update: Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1]
Summary
A Phase 1 study of venetoclax for Blastic Plasmacytoid Dendritic Cell Neoplasm has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 1 | Status: COMPLETED